6/17
06:13 am
auph
Strength Seen in Aurinia (AUPH): Can Its 5.6% Jump Turn into More Strength? [Yahoo! Finance]
Low
Report
Strength Seen in Aurinia (AUPH): Can Its 5.6% Jump Turn into More Strength? [Yahoo! Finance]
6/14
12:28 pm
auph
Aurinia Announces 2024 Annual General Meeting Results [Yahoo! Finance]
Medium
Report
Aurinia Announces 2024 Annual General Meeting Results [Yahoo! Finance]
6/14
12:16 pm
auph
Aurinia Announces 2024 Annual General Meeting Results
Medium
Report
Aurinia Announces 2024 Annual General Meeting Results
6/8
09:44 am
auph
We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) CEO For Now [Yahoo! Finance]
Low
Report
We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) CEO For Now [Yahoo! Finance]
6/7
11:34 am
auph
ILJIN SNT Co., Ltd. Announces Its Intention to Vote Against Aurinia Pharmaceuticals's Revised Equity Incentive Plan Proposal [Yahoo! Finance]
Low
Report
ILJIN SNT Co., Ltd. Announces Its Intention to Vote Against Aurinia Pharmaceuticals's Revised Equity Incentive Plan Proposal [Yahoo! Finance]
6/5
06:09 am
auph
Aurinia Presents Safety and Efficacy Profile of LUPKYNIS® for People with Lupus Nephritis at European Alliance of Associations for Rheumatology (EULAR) Congress 2024 [Yahoo! Finance]
Medium
Report
Aurinia Presents Safety and Efficacy Profile of LUPKYNIS® for People with Lupus Nephritis at European Alliance of Associations for Rheumatology (EULAR) Congress 2024 [Yahoo! Finance]
6/5
06:00 am
auph
Aurinia Presents Safety and Efficacy Profile of LUPKYNIS® for People with Lupus Nephritis at European Alliance of Associations for Rheumatology (EULAR) Congress 2024
Medium
Report
Aurinia Presents Safety and Efficacy Profile of LUPKYNIS® for People with Lupus Nephritis at European Alliance of Associations for Rheumatology (EULAR) Congress 2024
6/4
05:42 pm
auph
Aurinia Addresses Dubious Proposals Put Forth by Lucien Selce [Yahoo! Finance]
Medium
Report
Aurinia Addresses Dubious Proposals Put Forth by Lucien Selce [Yahoo! Finance]
6/4
05:30 pm
auph
Aurinia Addresses Dubious Proposals Put Forth by Lucien Selce
Medium
Report
Aurinia Addresses Dubious Proposals Put Forth by Lucien Selce
6/4
04:28 am
auph
The role of CAR-T cells in systemic lupus erythematosus [Yahoo! Finance]
Low
Report
The role of CAR-T cells in systemic lupus erythematosus [Yahoo! Finance]
6/3
06:43 pm
auph
Aurinia Provides Update on Proxy Statement [Yahoo! Finance]
Low
Report
Aurinia Provides Update on Proxy Statement [Yahoo! Finance]
6/3
06:30 pm
auph
Aurinia Provides Update on Proxy Statement
Low
Report
Aurinia Provides Update on Proxy Statement
6/3
08:29 am
auph
Aurinia Pharmaceuticals Shareholder Urges Fellow Shareholders to Withhold Support for CEO Peter Greenleaf [Yahoo! Finance]
Low
Report
Aurinia Pharmaceuticals Shareholder Urges Fellow Shareholders to Withhold Support for CEO Peter Greenleaf [Yahoo! Finance]
6/3
08:00 am
auph
Aurinia Pharmaceuticals Shareholder Urges Fellow Shareholders to Withhold Support for CEO Peter Greenleaf
Low
Report
Aurinia Pharmaceuticals Shareholder Urges Fellow Shareholders to Withhold Support for CEO Peter Greenleaf
5/30
06:00 am
auph
Aurinia Will Attend 2024 Jefferies Global Healthcare Conference
Low
Report
Aurinia Will Attend 2024 Jefferies Global Healthcare Conference
5/26
10:19 am
auph
Shareholders in Aurinia Pharmaceuticals (NASDAQ:AUPH) have lost 64%, as stock drops 9.5% this past week [Yahoo! Finance]
Low
Report
Shareholders in Aurinia Pharmaceuticals (NASDAQ:AUPH) have lost 64%, as stock drops 9.5% this past week [Yahoo! Finance]
5/20
09:11 pm
auph
ILJIN SNT Co., Ltd. Calls for Board Restructure at Aurinia Pharmaceuticals [Yahoo! Finance]
Medium
Report
ILJIN SNT Co., Ltd. Calls for Board Restructure at Aurinia Pharmaceuticals [Yahoo! Finance]
5/14
06:13 am
auph
Analysis Showing LUPKYNIS® is a Cost-Effective Treatment for Lupus Nephritis Presented at National Kidney Foundation's Spring Clinical Meeting 2024 [Yahoo! Finance]
Medium
Report
Analysis Showing LUPKYNIS® is a Cost-Effective Treatment for Lupus Nephritis Presented at National Kidney Foundation's Spring Clinical Meeting 2024 [Yahoo! Finance]
5/14
06:00 am
auph
Analysis Showing LUPKYNIS® is a Cost-Effective Treatment for Lupus Nephritis Presented at National Kidney Foundation’s Spring Clinical Meeting 2024
Medium
Report
Analysis Showing LUPKYNIS® is a Cost-Effective Treatment for Lupus Nephritis Presented at National Kidney Foundation’s Spring Clinical Meeting 2024
5/9
06:10 am
auph
Aurinia Presents Data Reinforcing LUPKYNIS® Safety and Efficacy for People with Lupus Nephritis at Congress of Clinical Rheumatology East 2024 [Yahoo! Finance]
Low
Report
Aurinia Presents Data Reinforcing LUPKYNIS® Safety and Efficacy for People with Lupus Nephritis at Congress of Clinical Rheumatology East 2024 [Yahoo! Finance]
5/9
06:00 am
auph
Aurinia Presents Data Reinforcing LUPKYNIS® Safety and Efficacy for People with Lupus Nephritis at Congress of Clinical Rheumatology East 2024
Low
Report
Aurinia Presents Data Reinforcing LUPKYNIS® Safety and Efficacy for People with Lupus Nephritis at Congress of Clinical Rheumatology East 2024
5/7
09:24 am
auph
Aurinia Pharmaceuticals Shareholder Urges Board of Directors to Take Action to Enhance Shareholder Value [Yahoo! Finance]
Low
Report
Aurinia Pharmaceuticals Shareholder Urges Board of Directors to Take Action to Enhance Shareholder Value [Yahoo! Finance]
5/7
09:00 am
auph
Aurinia Pharmaceuticals Shareholder Urges Board of Directors to Take Action to Enhance Shareholder Value
Low
Report
Aurinia Pharmaceuticals Shareholder Urges Board of Directors to Take Action to Enhance Shareholder Value
5/7
06:00 am
auph
Aurinia Will Attend 2024 RBC Capital Markets Global Healthcare Conference
Low
Report
Aurinia Will Attend 2024 RBC Capital Markets Global Healthcare Conference
5/3
11:32 pm
auph
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
Low
Report
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.